Skip to main content
VCbacked
Log inGet Started

Eagle Genomics

Cambridge, United Kingdom

Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data.

$3.6M raised
Sep 2023
Venture - Series Unknown
BiotechnologyCloud ComputingGeneticsOpen SourceSoftware

Top Investors

ETF PartnersInnovate UKFuture Planet CapitalAberdeenMidven

Founder Contacts

19,000+ verified contacts
Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Eagle Genomics

How much funding has Eagle Genomics raised?
Eagle Genomics has raised $3.6M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in September 2023.
Who are Eagle Genomics's investors?
Eagle Genomics's investors include ETF Partners, Innovate UK, Future Planet Capital, Aberdeen, Midven.
Where is Eagle Genomics headquartered?
Eagle Genomics is headquartered in Cambridge, United Kingdom.
What does Eagle Genomics do?
Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data.
What stage is Eagle Genomics at?
Eagle Genomics is at the Venture - Series Unknown stage.
Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .

MLA
"Eagle Genomics — Funding & Investors." VCBacked, September 27, 2023, https://www.vcbacked.co/company/eagle-genomics. Accessed June 4, 2026.
APA
VCBacked. (2023). Eagle Genomics — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/eagle-genomics
Wikipedia (cite web)
{{cite web |title=Eagle Genomics — Funding & Investors |url=https://www.vcbacked.co/company/eagle-genomics |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated .

Similar Companies in Biotechnology

View all
Virtuoso Surgical
Nashville
Pharvaris
Zug
Odyssey Therapeutics
Boston$213.0M
Tempus
Chicago
Anagram Therapeutics
Boston
Prenetics
Hong Kong